Venetoclax
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
OHSU Knight Cancer InstituteSmall moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
Rapamycin OHSU Knight Cancer Institute | Phase 2 | B |
TACROLIMUS Fred Hutchinson Cancer Center | Phase 2 | B |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | B |
Carboplatin OHSU Knight Cancer Institute | Phase 2 | B |
View all 50 →
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →